Why Goldman Sachs initiated 'buy' on Torrent Pharmaceuticals
Goldman Sachs has initiated coverage on Torrent Pharmaceuticals with a ‘buy’ rating and a target price of Rs 3,400. The brokerage firm believes that the company is able to maintain its margins. CNBC-TV18’s Nimesh Shah has more details.
Goldman Sachs has initiated coverage on Torrent Pharmaceuticals with a ‘buy’ rating and a target price of Rs 3,400. The brokerage firm believes that the company is able to maintain its margins.
CNBC-TV18’s Nimesh Shah has more details.
To watch other videos in this series, click on the Standout Brokerage Report tab below.
(Edited by : Niral Sharma)
First Published: Jan 19, 2021 10:55 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Punjab Lok Sabha elections: Check full list of AAP candidates and constituencies
May 18, 2024 12:59 PM
PM Modi, Rahul Gandhi election rallies in Delhi today: Here are the routes to avoid
May 18, 2024 11:28 AM